Cite
HARVARD Citation
Kim, D. et al. (n.d.). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet oncology. 17 (4), pp. 452-463. [Online].